Find the latest news about our company,
products, and people

Real-world study of 6,000+ Medicare patients shows adding PROVENGE® (sipuleucel-T) to the mCRPC treatment regimen reduced risk of death by 45%

New data presented at ASCO Genitourinary Cancers Symposium finds adding PROVENGE® to commonly prescribed oral therapies extends median survival by 14.5 months

Learn More

Media Coverage

Show More

Press Releases

Show More

Join Us

If you’re passionate about making a real difference for people living with cancer, you will be in good company.

Discover Opportunities

important safety information